SCHEMBL7065889

SCHEMBL7065889

CC(C)CC(NS(=O)(=O)c1cc(Cl)ccc1Cl)C(=O)O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.77
ALDH1A1 P00352 2/20 0.60
PSMB5 P28074 1/20 0.60
CYP2C19 P33261 1/20 0.60
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
HTT P42858 2/20 0.52
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP3 P08254 1/20 0.50
MMP7 P09237 1/20 0.50
MMP9 P14780 1/20 0.50
MMP13 P45452 1/20 0.50
GRN P28799 3/20 0.49
SORT1 Q99523 3/20 0.49
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8840147 0.81 MMP2 (0.69) KDM4EALDH1A1CYP2C19MMP1MMP2
SCHEMBL7062306 0.81 MMP2 (0.69) KDM4EALDH1A1CYP2C19MMP1MMP2
SCHEMBL7065982 0.80 RAB9A (0.67) KDM4EALDH1A1CYP2C19CA1CA2
SCHEMBL16000114 0.77 MCL1 (0.57) KDM4EALDH1A1HTTLMNAMAPT
SCHEMBL7066799 0.76 KDM4E (0.59) KDM4EALDH1A1CYP2C19CA1CA2
SCHEMBL28826809 0.76 PSMB5 (1.00) PSMB5MMP1MMP2MMP9
SCHEMBL29755775 0.76 PSMB5 (1.00) PSMB5MMP1MMP2MMP9
SCHEMBL7418075 0.75 MMP7 (0.55) KDM4EALDH1A1PSMB5HTTMMP7
SCHEMBL8068070 0.75 RAB9A (0.54) KDM4EALDH1A1PSMB5HTTLMNA
SCHEMBL4867847 0.75 GAA (0.64) MMP1MMP2MMP3MMP7MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US claimed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US claimed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP claimed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO claimed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 KDM4E 3988/4885ALDH1A1 3364/4885PSMB5 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.